NCT04470544View on ClinicalTrials.gov

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

December 22, 2021

Study Completion Date

January 20, 2022

Conditions
Severe Acute Respiratory Syndrome
Interventions
DRUG

Camostat Mesilate

Given PO

OTHER

Standard of Care

At Investigator discretion

Trial Locations (2)

85259

Mayo Clinic in Arizona, Scottsdale

85712

Tucson Medical Center, Tucson

All Listed Sponsors
lead

Alan Bryce

OTHER

NCT04470544 - Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 | Biotech Hunter | Biotech Hunter